



## MEETING AGENDA


### Pharmacy and Therapeutics Committee

Virtual Meeting

January 15, 2025 12:00PM – 5:00PM

Registration: <https://events.teams.microsoft.com/event/388d180c-74eb-47d2-bf56-cdedd465302e@eacd16bf-dc0e-44db-8e3f-be370c71feca>

TIME	TOPIC/PRESENTER
12:00 PM	<b>Welcome &amp; Introductions:</b> Suzanne Berman, RPH, AHCCCS Pharmacy Director
12:10 PM	<b>Minutes Review &amp; Vote - P&amp;T October 15, 2024:</b> Suzanne Berman
12:15 PM	<p><b>Supplemental Rebate Drug Class Review:</b> Clinical review by Umang Patel, PharmD, Magellan/Prime Therapeutics</p> <ol style="list-style-type: none"> <li>1. <b>Androgenic Agents</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>2. <b>Antidepressants, Other</b> <ol style="list-style-type: none"> <li>a. Written Testimony:                             <ol style="list-style-type: none"> <li>i. Kristina Sabetta</li> </ol> </li> </ol> </li> <li>3. <b>Antidepressants, SSRIs</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>4. <b>Antivirals, Topical</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>5. <b>Bone Resorption Suppression and Related Agents</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>6. <b>Bronchodilators, Beta Agonists</b> <ol style="list-style-type: none"> <li>a. Oral Testimony: Christine Dubé</li> </ol> </li> <li>7. <b>Enzyme Replacement Products, Gaucher Disease</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>8. <b>Erythropoiesis Stimulating Proteins</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>9. <b>Hypoglycemics, Alpha Glucosidase Inhibitors</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>10. <b>Hypoglycemics, Metformins</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>11. <b>Hypoglycemics, SGLT2s</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>12. <b>Immunoglobulins</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>13. <b>Oncology, Oral - Hematologics</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>14. <b>Ophthalmics, Anti-inflammatory/Immunomodulators</b></li> </ol>



## MEETING AGENDA

	<ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul> <p><b>15. Otic Antibiotics</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul> <p><b>16. Pulmonary Arterial Hypertension Agents</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul> <p><b>17. Thrombopoiesis Stimulating Agents</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul> <p><b>18. Ulcerative Colitis</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul>
<b>3:00 PM</b>	<p><b>New Drug Reviews: Umang Patel</b></p> <ul style="list-style-type: none"> <li><b>1. Yorvipath - palopegteriparatide</b> <ul style="list-style-type: none"> <li>a. Oral Testimony: Michele Rayes, Tracey Maravilla</li> </ul> </li> <li><b>2. Hymravzi - marstacimab-hncq</b></li> <li><b>3. Livdelzi - seladelpar</b> <ul style="list-style-type: none"> <li>a. Oral Testimony: Natalie Rose</li> </ul> </li> <li><b>4. Aqneursa - levacetylleucine</b> <ul style="list-style-type: none"> <li>a. Oral Testimony: Beth Zanrucha</li> </ul> </li> <li><b>5. Miplyffa - arimoclomol</b></li> <li><b>6. Ebglyss - lebrikizumab-lbkz</b></li> <li><b>7. Voranigo - vorasidenib</b></li> </ul>
<b>3:15 PM</b>	<b>Break &amp; Executive Session: Amber Small, PharmD, Magellan/Prime Therapeutics</b>
<b>4:30 PM</b>	<b>Public Therapeutic Class Votes: Umang Patel/Amber Small</b>
<b>4:45 PM</b>	<b>Biosimilar Update: Suzi Berman</b>
<b>4:50 PM</b>	<p><b>Meeting Adjournment</b></p> <p>2025 Meeting Dates: May 20 &amp; October 22</p>